Oventus Medical Limited (ASX:OVN) announced a share purchase plan to the market on 22 June 2017. Oventus wishes to advise that the closing date for the SPP will be extended from Wednesday 19 July 2017 to Monday 31 July 2017.
Australian medical device company, Oventus Medical Ltd. (ASX:OVN) has received FDA 510k clearance for its O2Vent W device, an oral appliance intended to reduce or alleviate snoring and mild to moderate obstructive sleep apnoea.
Regeneus (ASX:RGS), a clinical-stage regenerative medicine company, today announced that the United States Patent Office has issued a notice of allowance for a patent covering the composition, manufacture and use of the secretion stem cell technology platform, known as Sygenus, to treat acne. We recently informed the market of the new name for the secretions platform in our Q2 2017 Update.
Regeneus Ltd (ASX:RGS) provides the Company's latest newsletter for the quarter ended 30 June 2017.
Cellmid Limited (ASX:CDY) is pleased to advise that the highest ranked paper Nature has published the results of a significant study showing for the first time that midkine, around which the Company holds extensive intellectual property rights, is a crucial agent in the promotion of melanoma metastasis.
Queensland Bauxite Ltd (ASX:QBL) is excited to announce that Medical Cannabis Limited has confirmed successful germination and growth rates of its pioneering winter Cannabis crop.
Oventus Medical Ltd (ASX:OVN) announced a share purchase plan to the market on 22 June 2017. The record date to be registered as a shareholder for participation in the SPP is Wednesday, 21 June 2017.
